MedTrace Logo

DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer

NCT05050760 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2023-01-31

No results posted yet for this study

Summary

To evaluate the safety and feasibility of DCF combined with camrelizumab in the treatment of locally advanced ESCC

Conditions

Interventions

DRUG

Camrelizumab

Camrelizumab 200mg IV D1，Q3W,and preoperative therapy with three cycles.

DRUG

DCF

DCF:Oxaliplatin (85mg/ m\^2, IV D1,Q3W.Docetaxel: 60 mg/m\^2 intravenous infusion for 60 minutes, D1,Q3W.Tegafur:BSA\<1.25\^2,40 mg/time,1.25\^2\<BSA\<1.5\^2,50 mg/time,BID ,after breakfast and dinner, continuous administration for 14 days, rest for 7 days, as a treatment cycle;Repeat every 3 weeks

Sponsors & Collaborators

  • Xijing Hospital

    lead OTHER

Principal Investigators

  • Jianjun Yang · Xijing Hospital

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05050760 on ClinicalTrials.gov